Article highlights
Recent identification of oncogenic cells within healthy tissues and the prevalence of indolent cancers found incidentally at autopsies reveal a greater complexity in tumor initiation than previously appreciated. The human body contains roughly 40 trillion cells of 200 different types that are organized within a complex three-dimensional matrix, necessitating exquisite mechanisms to restrain aberrant outgrowth of malignant cells that have the capacity to kill the host. Understanding how this defense is overcome to trigger tumorigenesis and why cancer is so extraordinarily rare at the cellular level is vital to future prevention therapies. In this review, we discuss how early initiated cells are protected from further tumorigenesis and the non-mutagenic pathways by which cancer risk factors promote tumor growth. By nature, the absence of permanent genomic alterations potentially renders these tumor-promoting mechanisms clinically targetable. Finally, we consider existing strategies for early cancer interception with perspectives on the next steps for molecular cancer prevention.
Recent identification of oncogenic cells within healthy tissues and the prevalence of indolent cancers found incidentally at autopsies reveal a greater complexity in tumor initiation than previously appreciated. The human body contains roughly 40 trillion cells of 200 different types that are organized within a complex three-dimensional matrix, necessitating exquisite mechanisms to restrain aberrant outgrowth of malignant cells that have the capacity to kill the host. Understanding how this defense is overcome to trigger tumorigenesis and why cancer is so extraordinarily rare at the cellular level is vital to future prevention therapies. In this review, we discuss how early initiated cells are protected from further tumorigenesis and the non-mutagenic pathways by which cancer risk factors promote tumor growth. By nature, the absence of permanent genomic alterations potentially renders these tumor-promoting mechanisms clinically targetable. Finally, we consider existing strategies for early cancer interception with perspectives on the next steps for molecular cancer prevention.
Groups
Group leader
Research topics & keywords
Meet the Research Team
The Cancer Origins group is dedicated to understanding how cancer begins, specifically, how oncogenic cells overcome normal tissue restraints, gain malignant potential, and initiate tumour formation. We are interested in how environmental exposures, such as air pollutants, shape the tissue microenvironment to support the expansion of latent oncogenic cells and promote lung cancer
Institute Fellow
All publications
https://royalsocietypublishing.org/rsob/article/16/8/260089/482862/CDK1-Cyclin-B-mediated-phosphorylation-of-PP2A-B56
CDK1-Cyclin B mediated phosphorylation of PP2A-B56 on B56Par1.T73T75 controls mitotic entry timing and Schizosaccharomyces pombe cell size
19 August 2026
Institute Authors (3)
Lenka Halova, Duncan Smith, Iain Hagan
Labs & Facilities
Biological Mass Spectrometry
Research Group
Cell Division
19 August 2026
https://www.cell.com/immunity/fulltext/S1074-7613(26)00278-5
CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity
4 August 2026
Institute Authors (10)
Erin Richardson, Shih-Chieh Chiang, Massimo Russo, Charles Earnshaw, Anna Pidoux, Poppy Dunn, Sudhakar Sahoo, Antonia Banyard, Natalia Moncaut, Santiago Zelenay
Labs & Facilities
BRU Experimental Team, Computational Biology Support, Genome Editing and Mouse Models, Mass and Flow Cytometry, Transgenic Breeding Team
Research Group
Cancer Inflammation and Immunity
4 August 2026
https://www.cell.com/cell/fulltext/S0092-8674(26)00522-2
Plasma signals of lung tumor promotion for molecular cancer prevention
25 June 2026
Institute Authors (1)
William Hill
Research Group
Cancer Origins
25 June 2026
https://link.springer.com/article/10.1038/s44319-026-00809-1
PKMYT1 has an important role in the timing and fidelity of chromosome segregation
5 June 2026
Institute Authors (6)
Asma Belbelazi, Charlie Greenaway-Wells, Zoe Edwards, Wendy Trotter, Keren Dawson, Iain Hagan
Research Group
Cell Division
5 June 2026
https://www.nature.com/articles/s42255-026-01514-y
Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion
27 April 2026
Institute Authors (4)
Amaya Virós, Noah Palombo, Charlotte Russell, Claus Jørgensen
Research Group
Skin Cancer & Ageing
27 April 2026
https://www.cell.com/cancer-cell/fulltext/S1535-6108(26)00114-5
Immunometabolic gatekeeping: How tissue metabolism conditions tumor immunity
13 April 2026
Institute Authors (1)
Samra Turajlić
Research Group
Cancer Dynamics
13 April 2026
Our Research
Our research spans the whole spectrum of cancer research from cell biology through to translational and clinical studies
Research Groups
Our research groups study many fundamental questions of cancer biology and treatment
Our Facilities
The Institute has outstanding core facilities that offer cutting edge instruments and tailored services from expert staff
Latest News & Updates
Find out all our latest news
Careers that have a lasting impact on cancer research and patient care
We are always on the lookout for talented and motivated people to join us. Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.



